Company Profile

Nanovis Inc
Profile last edited on: 5/12/17      CAGE: 4PA81      UEI:

Business Identifier: Nanotechnology-driven surgical implants: cervical and lumbar interbody fusion devices
Year Founded
2006
First Award
2010
Latest Award
2015
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5865 East State Road 14
Columbia City, IN 46725
   (877) 907-6266
   customer.service@nanovisinc.com
   www.nanovisinc.com
Location: Single
Congr. District: 03
County: Whitley

Public Profile

Nanovis is a nanotechnology-driven surgical implant company using their broad portfolio of bone adhesion peptides to create implants and biomaterials designed to reduce stability and infection related complications by increasing bone on growth and reducing bacteria colonization. Nanovis’ technology includes nanopatterned surfaces on implant metals, polymers, ceramics and ceramic composites as well as bone growth peptides, carbon nanofibers and self assembling nanomaterials. Nanovis' interests are in reducing implant complications related to stability and bacteria colonization. While the firm’s technologies are helpful across the spectrum of orthopedics, they are choosing to focus their development efforts towards launching differentiated implants in the $10 billion spinal implant market. Nanovis’ scientists have invented a wide range of nanosurfaces intended to increase tissue to implant bone on growth on a wide range of implant materials from titanium to polypropylene to polyetheretherketone (PEEK). The nanosurfaces have increased markers for bone on growth on a wide range of materials in vitro in three successful short and long term in vivo pilots, with observed trends toward increased bone on growth on the firms nano surfaced titanium alloy compared to conventional titanium alloy. Nanovis has acquired and is developing an important set of bone growth peptides. These peptides are suitable for delivery as a combination product with our nanostructured biomaterials and are designed to provide a complementary mechanism of action. Nanovis is pursuing nanostructured biomaterial/bone growth peptide programs primarily in the orthopedic fields. Taken together, Nanovis’ innovative nanostructured biomaterials and bone growth peptides provide an important set of products for Nanovis’ orthopedic strategy. Nanovis Nanosurface intellectual property, expertise and experience covers a wide array of polymer, metal and ceramic implant materials. Nanovis, frequently in collaboration with strategic partnerships is developing implant nanosurfaces to improve the clinical outcomes for dental, orthopedic, soft tissue repair, urogenital, cardiovascular and neurosurgical

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  Matt Hedrick -- Chief Executive Officer

  Julie Chandler -- Vice President, Business Development

  Brian More -- Chief Financial Officer

  Chang Yao -- Chief Scientific Officer

  Chang Yao